SAAKSHI MEDTECH AND PANELS LIMITED

Regd. Office Address: Plot No. El-23, J Block, MIDC Industrial Area, Bhosari, Pune - 411026, Maharashtra, India, 411026

Email Id: aniket.l@smtpl.co **Website:** www.smtpl.co

Contact Details: 020 39854400 / 020 39854401

Date: August 07, 2026

To,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East)
Mumbai 400051

ISIN: **INE0PSK01027**
Symbol: **SAAKSHI**

Dear Sir/Madam,

Subject: Receipt of In-Principle Approval from NSE for proposed preferential issue.

In compliance with Regulation 30 read with Schedule III, Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**") read with SEBI master circular dated November 11, 2024 on SEBI Listing Regulations, this is to inform you that the Company has received In-Principle approval from NSE vide letter no. NSE/LIST/55094 dated August 06, 2026 under Regulation 28(1) of SEBI Listing Regulations for issue of 2022940 equity shares on preferential basis.

The information required under Regulation 30 read with SEBI master circular dated November 11, 2024 is enclosed as **Annexure-A.** The Copy of approval received from NSE is enclosed herewith.

Thanking You,

For Saakshi Medtech and Panels Limited

Mayuri Aniket Latkar
Digitally signed by Mayuri Aniket Latkar
Date: 2026.08.07 11:42:43 +05'30'

Mrs. Mayuri Aniket Latkar
Chief Financial Officer and Director
DIN: 03312077

SAAKSHI MEDTECH AND PANELS LIMITED

Regd. Office Address: Plot No. El-23, J Block, MIDC Industrial Area, Bhosari, Pune - 411026, Maharashtra, India, 411026

Email Id: aniket.l@smtpl.co **Website:** www.smtpl.co

Contact Details: 020 39854400 / 020 39854401

Annexure-A

The details as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI master circular dated November 11, 2024 are mentioned below:

Sr. No.	Particulars	Details
1.	Name of the Regulatory or licensing authority	NSE
2.	Brief details of the approval/license obtained/~~withdrawn/surrendered~~	In-Principle approval from NSE vide letter no. NSE/LIST/55094 dated August 06, 2026 under Regulation 28(1) of SEBI Listing Regulations for issue of 2022940 equity shares of face value of Rs. 10 /- to be allotted on preferential basis.
3.	Impact/relevance of such approval/~~license~~ to the listed entity	NSE has granted in-principle approval for the proposed share swap transaction with Laxmi Engineering Industries Bhopal Pvt Ltd (Target Company), enabling the Company to issue 20,22,940 equity shares to the promoters at an issue price of Rs. 207/- per equity share for consideration other than cash (share swap).
4.	Withdrawal/cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons, for such action, estimated impact (monetary or otherwise) on the listed entity and penalty. If any	NA
5.	Period for which such approval/~~license~~ is valid	The Approval is valid for fifteen days from the date of NSE approval.
6.	The Actual impact (monetary or otherwise) along with corrective actions taken by the listed Company pursuant to the withdrawal, cancellation or suspension of the key license/approval	Not Applicable

Ref: NSE/LIST/55094 August 06, 2026

The Company Secretary
Saakshi Medtech and Panels Limited

Dear Sir/Madam,

Sub: In - Principle approval under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We are in receipt of your application regarding In-principle approval for issue of 2022940 Equity shares of Rs. 10/- each to be issued through Preferential issue in terms of Regulation 28(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. In this regard, the Exchange is pleased to grant in-principle approval for the said issue subject to the Company fulfilling the following conditions:

1. Filing the listing application at the earliest from the date of allotment.
2. Receipt of statutory and other approvals and compliance of guidelines/regulations issued by the statutory authorities including SEBI, RBI, MCA, etc.
3. Compliance with all the applicable guidelines, regulations, directions of the Exchange or any statutory authorities as on the date of listing application.
4. Compliance of all conditions as per the SEBI (LODR) Regulations, 2015 as on date of listing, Companies Act, 1956 / Companies Act, 2013 and other applicable laws.
5. Submissions of documents as may be required by NSE and payment of applicable fees.

Further, the company is advised to strengthen internal controls (to monitor trades being executed by the proposed allottees in the scrip of the company) before allotment of securities in order to avoid any non-compliances in respect of trades being executed by the allottees in contravention of provisions of Chapter V of SEBI (ICDR) Regulations. In this regard,

a) The Company is advised to obtain an undertaking from the allottee(s) confirming that they shall not do intra-day trading in the scrip of the company or any sale in the scrip of the company till the allotment date of the security as required under SEBI (ICDR) Regulations.
b) The Company may note that the responsibility/onus is solely on the Issuer company to verify the above (a) and ensure compliance with applicable provisions including Regulation 167(6) of SEBI ICDR regulations, 2018.
c) The Company may also note that any non-compliances, if observed by the exchanges post the undertaking and verification by the Issuer company may impact the listing of such shares.

Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any.
The Exchange reserves its right to withdraw its in-principle approval at a later stage if the

This Document is Digitally Signed

Signer: POOJA RISHIKESH PASHTE
Date: Thu, Aug 6, 2026 16:30:41 IST
Location: NSE

information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc.

Yours faithfully,
For National Stock Exchange of India Limited

Pooja Pashte
Manager

Cc:
National Securities Depository Limited
Central Depository Services Limited

P.S. Checklist of all the further issues is available on website of the exchange at the following URL: https://www.nseindia.com/companies-listing/raising-capital-further-issuesmain-sme-checklist

The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application. The app can be downloaded from the App Store/ Play store with the name "NEAPS APP"

This Document is Digitally Signed

Signer: POOJA RISHIKESH PASHTE
Date: Thu, Aug 6, 2026 16:30:41 IST
Location: NSE